EMCURE vs NEULANDLAB: Stock Comparison
EMCURE PHARMACEUTICALS L is the larger company by market capitalisation. EMCURE PHARMACEUTICALS L shows a lower P/E and a higher ROE, while NEULAND LAB shows a higher dividend yield, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
EMCURE leads 5; NEULANDLAB leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | EMCURE | NEULANDLAB |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | EMCURE | NEULANDLAB |
|---|---|---|
| Live Price | ₹1,927.6 | ₹22,660 |
| Day Change | 3.93% | -1% |
| Volume | 2.77 L | 21,110 |
| 52-Week High | ₹2,048 | ₹23,881 |
| 52-Week Low | ₹1,260 | ₹11,500 |
| Distance from 52W High | -5.88% | -5.11% |
Valuation
| Metric | EMCURE | NEULANDLAB |
|---|---|---|
| Market Cap | ₹36,661 Cr | ₹29,101 Cr |
| P/E Ratio | 34.81x | 59.08x |
| P/B Ratio | 7.11x | 15.69x |
| EPS | ₹15.5 | ₹115.1 |
| Book Value | ₹262.37 | ₹1,461.02 |
| Dividend Yield | 0% | 0.15% |
Growth
| Metric | EMCURE | NEULANDLAB |
|---|---|---|
| Revenue Growth (TTM YoY) | 16.7% | 136.4% |
| EPS Growth (TTM YoY) | 28.8% | 664.4% |
| Qtr Sales Growth | 77.85% | 0% |
| Qtr Profit Growth | 46.17% | 0.21% |
Profitability & Leverage
| Metric | EMCURE | NEULANDLAB |
|---|---|---|
| ROE | 19.75% | 19.46% |
| ROCE | 16.28% | 19.06% |
| Net Margin | 10.04% | 17.99% |
| Operating Margin | 20.26% | 25.29% |
| Debt to Equity | 0.37x | 0.11x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | EMCURE | NEULANDLAB |
|---|---|---|
| Promoter Holding | 77.6%▼ 0.04 pp | 32.62%▼ 0.01 pp |
| FII Holding | 4.88%▲ 1.53 pp | 21.08%▲ 0.62 pp |
| DII Holding | 8.46%▲ 2.36 pp | 16.51%▲ 0.67 pp |
| Public Holding | 8.83%▼ 3.85 pp | 29.79%▼ 1.28 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: EMCURE PHARMACEUTICALS L and NEULAND LAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.